홈
규제 업데이트2026년 9월 4일•1분 읽기

FDA Approves Multiple Labeling Updates for Levetiracetam Oral Solution

작성: PharmaCountry 팀

The FDA has approved several labeling supplement submissions for the discontinued oral solution Levetiracetam (100 mg/mL) spanning from 2011 to 2024.

The FDA’s drug approval database lists an oral solution of Levetiracetam (100 mg/mL) under product number 001. The product is marked as discontinued and is not a reference drug. Since the original approval (submission 1, ORIG) on 17 Oct 2011, the agency has approved a series of labeling supplement (SUPPL) submissions for this product. Approved submissions include numbers 1 (03 Nov 2014), 3 (12 Mar 2013), 6 (03 Nov 2014), 9 (24 Dec 2015), 10 (24 Dec 2015), 13 (16 Mar 2023), 14 (16 Mar 2023), 15 (date incomplete), 18 (16 Mar 2023), 20 (16 Mar 2023), 22 (24 Oct 2023), and 23 (22 Nov 2024). All listed submissions have a status of AP (Approved) and pertain to labeling updates.

PharmaCountry 팀이 정리했습니다 · 출처: FDA.gov